Tower Research Capital LLC (Trc) Allogene Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 11,055 shares of ALLO stock, worth $13,597. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,055
Previous 17,594
37.17%
Holding current value
$13,597
Previous $19,000
31.58%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding ALLO
# of Institutions
181Shares Held
138MCall Options Held
76.6KPut Options Held
36.2K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$23 Million1.5% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$20.2 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il14MShares$17.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.02MShares$11.1 Million0.0% of portfolio
-
Primecap Management CO Pasadena, CA7.08MShares$8.71 Million0.01% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $177M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...